HER2-Positive Metastatic Breast Cancer Patient Selection and Treatment Duration Considerations

Dr. Kruse discusses evolving perspectives on patient selection for T-DXd-based therapy, noting significant changes in her approach over the past year. Initially, she attempted to identify specific populations most likely to benefit, but increasing experience suggests this selective approach may disadvantage patients who could achieve superior outcomes.

Her current strategy involves starting with T-DXd plus pertuzumab as the intended plan, then evaluating patient-specific circumstances that might present challenges. Obvious contraindications include significant pulmonary comorbidities, but many patients tolerate T-DXd well with appropriate modifications over time.

De novo metastatic patients represent a population where she feels particularly strongly about T-DXd plus pertuzumab, given their typical sensitivity to first-line therapy and potential for deep responses. These patients tend to be younger with higher disease volume, representing optimal candidates for intensive combination therapy.

Dr. Rao emphasizes the clinical significance of deep responses in changing patient counseling approaches. Historically, stable disease was considered acceptable in metastatic settings, but emerging data suggests patients achieving complete responses and deep partial responses demonstrate superior durability compared to standard partial responses.

The 24-month progression-free survival rates were significantly better for patients with complete responses and deep partial responses, influencing discussions about treatment duration and expectations. This creates more complex conversations with patients about long-term disease control possibilities and quality-of-life considerations during extended therapy periods.

Both panelists acknowledge that integrating these insights with existing effective therapies like those from the PATINA and HER2CLIMB trials creates additional complexity in treatment sequencing decisions that will continue evolving with longer follow-up data.